SCHEMBL741012

SCHEMBL741012

CCOC(=O)n1nc(NC(=O)c2cccs2)c2cc(C(=O)O)sc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.47
HPGD P15428 9/20 0.47
ALDH1A1 P00352 8/20 0.47
HSD17B10 Q99714 7/20 0.47
KMT2A Q03164 5/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
CASP1 P29466 5/20 0.47
MEN1 O00255 4/20 0.47
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
TP53 P04637 3/20 0.47
MAPK1 P28482 8/20 0.46
TDP1 Q9NUW8 7/20 0.46
L3MBTL1 Q9Y468 6/20 0.46
LMNA P02545 3/20 0.46
NPSR1 Q6W5P4 6/20 0.45
MAPT P10636 5/20 0.45
CASP7 P55210 3/20 0.45
TSHR P16473 2/20 0.45
BAP1 Q92560 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL742599 0.89 KDM4E (0.46) KDM4EHPGDALDH1A1HSD17B10KMT2A
SCHEMBL738735 0.86 KDM4E (0.43) KDM4EHPGDALDH1A1HSD17B10KMT2A
SCHEMBL740278 0.86 KDM4E (0.43) KDM4EHPGDALDH1A1HSD17B10KMT2A
SCHEMBL741636 0.85 KDM4E (0.42) KDM4EHPGDALDH1A1HSD17B10KMT2A
SCHEMBL739772 0.83 KDM4E (0.41) KDM4EHPGDALDH1A1HSD17B10KMT2A
SCHEMBL742570 0.82 ALDH1A1 (0.40) KDM4EHPGDALDH1A1HSD17B10KMT2A
SCHEMBL739402 0.82 KDM4E (0.46) KDM4EHPGDALDH1A1HSD17B10KMT2A
SCHEMBL742843 0.82 LMNA (0.47) KDM4EHPGDALDH1A1KMT2ATP53
SCHEMBL1262154 0.82 KDM4E (0.44) KDM4EHPGDALDH1A1HSD17B10KMT2A
SCHEMBL741290 0.80 P2RY14 (0.40) KDM4EHPGDALDH1A1HSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481584-B2 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-07-09 US disclosed
US-20120165311-A1 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-06-28 US disclosed
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 US disclosed
EP-1711177-B1 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS PFIZER ITALIA SRL (IT) 2008-05-28 EP disclosed
EP-1711177-A1 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS Pfizer Italia S.r.l. (IT) 2006-10-18 EP disclosed
US-20050187209-A1 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors PHARMACIA ITALIA S.P.A. (IT) 2005-08-25 US disclosed
WO-2005074922-A1 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS PFIZER ITALIA S.R.L. (IT) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165311-A1 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K3 KDM4E 1435/4885HPGD 1590/4885ALDH1A1 1584/4885
US-20050187209-A1 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors MAP3K19, MAP3K1, MAP3K3 KDM4E 1432/4885HPGD 1650/4885ALDH1A1 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.